Hormone Therapy News

Women who used hormone replacement therapy — even only for a few years — demonstrated an increased risk for serous and endometrioid ovarian cancer, according to study results.

Both the etonogestrel implant and the 52-mg levonorgestrel IUD are safe and effective when used beyond the current FDA-approved usage duration, according to a recently published study.

Vertebral fractures were associated with cortisol secretion and sensitivity in postmenopausal women with type 2 diabetes, according to research published in the Journal of Clinical Endocrinology & Metabolism.

A lipoprotein-based insulin resistance index, very low density lipoprotein particle concentration and size, triglycerides and their ratio with HDL cholesterol were associated with incident diabetes across a range of ages and ethnicities, according to research published in Diabetes Care.

In postmenopausal women undergoing hormone therapy, a low-dose regimen does not appear to differ from the standard dose or placebo in its effects on weight, BMI, blood pressure, C-reactive protein or HDL cholesterol, according to recent findings.

No convincing evidence exists to link increased cardiovascular risks with testosterone therapy, according to a review published in Mayo Clinic Proceedings.

There may be an increased risk for the development of a rare tumor, glioma of the brain, among premenopausal women taking a hormonal contraceptive for at least 5 years, according to recent study findings published in the British Journal of Clinical Pharmacology.

Prader-Willi syndrome is a complex neurodevelopmental disorder caused by the lack of paternally derived genetic material in the chromosome region 15q11-13. This rare disorder is characterized by many endocrinopathies, as well as intellectual disability and a distinctive behavioral phenotype, all of which present lifelong challenges for affected individuals. The defining feature of Prader-Willi syndrome is hyperphagia, typically presenting in early to middle childhood. The overwhelming drive to eat, coupled with reduced energy expenditure and decreased caloric requirements, leads to morbid obesity unless food intake is strictly controlled.

In postmenopausal women who are overweight, weight loss led to small increases in follicle-stimulating hormone, according to research published in Obesity.

Bioavailable testosterone could play a key role in the redistribution of visceral and subcutaneous fat in the central abdominal region in women during menopause, according to findings published in Obesity.